MicroRNA signature at the time of clinical HCV recurrence associates with aggressive fibrosis progression post-liver transplantation

American Journal of Transplantation

Volumn 13, Issue 3, 2013, Pages 729-737

  Gehrau, R C ^a   Mas, V R ^a   Villamil, F G ^b   Dumur, C I ^a   Mehta, N K ^a   Suh, J L ^b   Maluf, D G ^a,c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Gene expression; HCV recurrence; hepatitis C virus; liver transplantation; microarray; microRNA; prediction

Indexed keywords

MICRORNA; MICRORNA 155; MICRORNA 222; MICRORNA 23B; MICRORNA 27B; MICRORNA 30C; MICRORNA 34A; MICRORNA 361; MICRORNA 455; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENE EXPRESSION; GRAFT RECIPIENT; HEPATITIS C; HIGH RISK PATIENT; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; LONG TERM CARE; LONGITUDINAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; RECURRENT DISEASE; RETROSPECTIVE STUDY; STEATOSIS;

ADULT; AGED; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GRAFT REJECTION; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RECURRENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER;

EID: 84874400437     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12047     Document Type: Article

References (50)

1. Rubin A, Aguilera V, Berenguer M,. Liver transplantation and hepatitis C. Clin Res Hepatol Gastroenterol 2011; 35: 805-812.
2. Kershenobich D, Razavi HA, Cooper CL, et al. Applying a system approach to forecast the total hepatitis C virus-infected population size: Model validation using US data. Liver Int 2011; 31 (Suppl 2): 4-17.
3. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW,. Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521, 521.e1-e6.
4. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-687.
5. Yilmaz N, Shiffman ML, Stravitz RT, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transplant 2007; 13: 975-983.
6. Campsen J, Blei AT, Emond JC, et al. Outcomes of living donor liver transplantation for acute liver failure: The adult-to-adult living donor liver transplantation cohort study. Liver Transplant 2008; 14: 1273-1280.
7. Rayhill SC, Wu YM, Katz DA, et al. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation 2007; 84: 331-339.
8. Forman LM,. To transplant or not to transplant recurrent hepatitis C and liver failure. Clin Liver Dis 2003; 7: 615-629.
9. Ciccorossi P, Maina AM, Oliveri F, et al. Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C. Liver Int 2007; 27: 612-619.
10. Berenguer M, Royuela A, Zamora J,. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: Results of a meta-analysis. Liver Transplant 2007; 13: 21-29.
11. Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: A prospective, randomized trial. Liver Transplant 2004; 10: 1258-1262.
12. Berenguer M, Aguilera V, San Juan F, et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 2010; 90: 1204-1209.
13. Berenguer M, Rayon JM, Prieto M, et al. Are posttransplantation protocol liver biopsies useful in the long term ? Liver Transplant 2001; 7: 790-796.
14. Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC, Trent Hepatitis C Study Group. Progression of hepatic fibrosis in patients with hepatitis C: A prospective repeat liver biopsy study. Gut 2004; 53: 451-455.
15. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transplant 2004; 10: 1240-1247.
16. Cholongitas E, Senzolo M, Standish R, et al. A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol 2006; 125: 710-721.
17. Bravo AA, Sheth SG, Chopra S,. Liver biopsy. N Engl J Med 2001; 344: 495-500.
18. Toniutto P, Fabris C, Bitetto D, et al. Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol Hepatol 2007; 22: 1904-1908.
19. Carrion JA, Fernandez-Varo G, Bruguera M, et al. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology 2010; 138: 147-58.e1.
20. Martinez SM, Fernandez-Varo G, Gonzalez P, et al. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 138-148.
21. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: A new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-1713.
22. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3: 8.
23. Cholongitas E, Tsochatzis E, Goulis J, Burroughs AK,. Noninvasive tests for evaluation of fibrosis in HCV recurrence after liver transplantation: A systematic review. Transpl Int 2010; 23: 861-870.
24. Mas V, Maluf D, Archer KJ, et al. Transcriptome at the time of hepatitis C virus recurrence may predict the severity of fibrosis progression after liver transplantation. Liver Transplant 2011; 17: 824-835.
25. Wang XW, Heegaard NH, Orum H,. MicroRNAs in liver disease. Gastroenterology 2012; 142: 1431-1443.
26. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
27. Desmet VJ, Knodell RG, Ishak KG, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis [Hepatology 1981;1:431-435]. J Hepatol 2003; 38: 382-386.
28. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
29. Pelletier SJ, Iezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL,. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: Persistent elevation of serum transaminase levels ver-sus necroinflammatory activity. Liver Transplant 2000; 6: 44-53.
30. Rustgi VK,. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 2007; 42: 513-521.
31. Farid WR, Pan Q, van der Meer AJ, et al. Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transplant 2012; 18: 290-297.
32. Chinnadurai R, Velazquez V, Grakoui A,. Hepatic transplant and HCV: A new playground for an old virus. Am J Transplant 2012; 12: 298-305.
33. Clark PJ, Thompson AJ,. Host genomics and HCV treatment response. J Gastroenterol Hepatol 2012; 27: 212-222.
34. Hashimoto K, Miller C, Hirose K, et al. Measurement of CD4+ T cell function in predicting allograft rejection and recurrent hepatitis C after liver transplantation. Clin Transplant 2010; 24: 701-708.
35. Gehrau R, Maluf D, Archer K, et al. Molecular pathways differentiate hepatitis C virus (HCV) recurrence from acute cellular rejection in HCV liver recipients. Mol Med 2011; 17: 824-833.
36. Van, Wynsberghe PM, Chan SP, Slack FJ, Pasquinelli AE,. Analysis of microRNA expression and function. Methods Cell Biol 2011; 106: 219-252.
37. Berenguer M,. Hot topic in hepatitis C virus research: The type of immunosuppression does not matter. Liver Transplant 2011; 17 (Suppl 3): S24-S28.
38. Guido M, Fagiuoli S, Tessari G, et al. Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut 2002; 50: 697-700.
39. Baiocchi L, Angelico M, Petrolati A, et al. Correlation between liver fibrosis and inflammation in patients transplanted for HCV liver disease. Am J Transplant 2008; 8: 673-678.
40. Li S, Chen X, Zhang H, et al. Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res 2009; 50: 1756-1765.
41. Pandit KV, Milosevic J, Kaminski N,. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res 2011; 157: 191-199.
42. Lu LF, Thai TH, Calado DP, et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 2009; 30: 80-91.
43. Thai TH, Calado DP, Casola S, et al. Regulation of the germinal center response by microRNA-155. Science 2007; 316: 604-608.
44. Rodriguez A, Vigorito E, Clare S, et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007; 316: 608-611.
45. Banerjee A, Schambach F, DeJong CS, Hammond SM, Reiner SL,. Micro-RNA-155 inhibits IFN-gamma signaling in CD4+ T cells. Eur J Immunol 2010; 40: 225-231.
46. O'Connell RM, Kahn D, Gibson WS, et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010; 33: 607-619.
47. Basha HI, Subramanian V, Seetharam A, et al. Characterization of HCV-specific CD4+Th17 immunity in recurrent hepatitis C-induced liver allograft fibrosis. Am J Transplant 2011; 11: 775-785.
48. Subramanian V, Seetharam AB, Vachharajani N, et al. Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation. Transplantation 2011; 92: 1259-1268.
49. Miossec P, Korn T, Kuchroo VK,. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361: 888-898.
50. Hammerich L, Heymann F, Tacke F,. Role of IL-17 and Th17 cells in liver disease. Clin Dev Immunol 2011; 345803: 1-12.